| Apr 27, 2026 | management_change | Abbott appointed Kevin Conroy to its Board of Directors and increased the board size to thirteen. |
|---|
| Apr 17, 2026 | legal_settlement | Abbott received preliminary court approval for a settlement in shareholder derivative lawsuits, including governance reforms. |
|---|
| Apr 16, 2026 | acquisition | Abbott completed Exact Sciences acquisition on March 23, 2026, becoming a leader in oncology diagnostics. |
|---|
| Apr 16, 2026 | Guidance: adjusted_diluted_eps | 1.25 to 1.31 |
|---|
| Apr 16, 2026 | Guidance: adjusted_diluted_eps | 5.38 to 5.58 |
|---|
| Apr 16, 2026 | Guidance: comparable_sales_growth | 6.50 to 7.50 |
|---|
| Apr 29, 2026 | mda_quarterly | Abbott's net sales increased 7.8% to $11.164 billion in Q1 2026, or 3.8% excluding favorable foreign exchange, while net earnings declined to $1.077 billion. The quarter was significantly shaped by the $20.6 billion acquisition of Exact Sciences, funded primarily by $20 billion in new long-term debt, establishing Abbott's position in cancer diagnostics with products like Cologuard®. This acquisition contributed $96 million to the Diagnostic Products segment, which also saw Core Laboratory growth on the Alinity® platform, offsetting a decline in Rapid and Molecular Diagnostics due to lower respiratory test demand.
Medical Devices led growth, up 8.1% excluding foreign exchange, driven by double-digit increases in Rhythm Management (Aveir® pacemakers), Electrophysiology (ablation catheters), and Heart Failure (ventricular assist devices), alongside strong Diabetes Care sales (CGM systems). Established Pharmaceutical Products grew 9.0% ex-FX, primarily in Key Emerging Markets. Nutritional Products sales decreased 7.7% ex-FX due to lower volumes.
Operating expenses rose, with SG&A up 22.2% due to Exact Sciences integration costs. The company faces significant tax disputes with the IRS (over $1 billion) and a $413 million Malaysian tax assessment, which it intends to vigorously defend. Cash and equivalents decreased to $6.8 billion due to the acquisition and debt repayment, while long-term debt significantly increased. Abbott maintains an investment-grade rating and increased its quarterly dividend by 6.8%. |
|---|
| Feb 20, 2026 | business | Abbott Laboratories is a global healthcare company engaged in the discovery, development, manufacture, and sale of a diversified line of products across four segments. Its Established Pharmaceutical Products segment markets branded generic pharmaceuticals, including Creon for gastroenterology and Synthroid for hypothyroidism, primarily in emerging markets, facing competition from generics. The Diagnostic Products segment offers a broad range of systems and tests globally, such as the Alinity family for immunoassay and molecular diagnostics (e.g., SARS-CoV-2, HIV), and rapid diagnostics like BinaxNOW, with products susceptible to rapid obsolescence. Nutritional Products include infant formulas like Similac and adult nutritionals such as Ensure and Glucerna, competing on innovation and consumer preference. The Medical Devices segment provides rhythm management (Aveir pacemakers), electrophysiology (TactiFlex), heart failure (HeartMate, CardioMEMS), vascular (XIENCE stents), structural heart (MitraClip, TriClip), diabetes care (FreeStyle Libre CGM), and neuromodulation (Proclaim, Infinity DBS) devices, also facing rapid obsolescence. Abbott is acquiring Exact Sciences to enter the cancer diagnostics market. The company operates under extensive global regulation, impacting product development, approval, pricing, and reimbursement, alongside cost containment pressures and evolving data privacy laws. |
|---|
